The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

A new survey suggests about three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro and ...

Social media influencers and supplement companies have stoked concerns, but experts say the issue is a lot more complicated.

GLP-1s are changing the menu landscape for restaurants as diners fundamentally change how they eat. Here's what you'll start ...

Consumer health advertising is driving many employees to take action on GLP-1s. But without guidance, those decisions could be risky.

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think ...

“GLP‑1s have effectively created a third pillar of pharmacy spend and most employers don't yet have a mature playbook to manage it,” Conway said, adding that over half of employers now cite GLP‑1s as ...

Combining GLP-1 medications with 8 healthy lifestyle habits reduced the risk of major adverse cardiovascular events, or MACE, ...

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one ...

FDA sends Novo Nordisk 2nd warning over GLP-1 ads for misleading claims in Ozempic promotion and risk disclosure violations.

GLP-1 receptor agonists hold key market opportunities due to their effectiveness in diabetes and obesity management, expanding to cardiovascular and neurodegenerative disorders. Innovations like oral ...